In a preliminary prospective study, eleven outpatients undergoing fibreoptic bronchoscopy using a titrated dose of topical lignocaine anaesthesia were studied. Patient comfort, lignocaine dosage and resultant plasma concentrations were measured at four stages during the procedure. Large total doses, mean 512 (SD 55) mg lignocaine, were frequent and systemic absorption was unpredictable with two patients having plasma concentrations in the toxic range (>5JAg/ml). Peak plasma concentrations, mean 2.3 (SD 1.4) JAg/ml, occurred 30 to 40 minutes after commencement of topical application and coincided with completion of the procedure. No correlation was found between the individual dose of lignocaine administered and either the resultant plasma concentration or patient comfort scores. In an effort to minimise potential lignocaine toxicity, a fixed total dose technique (lignocaine 370 mg) was studied in a further twenty-one patients. No change in patient comfort scores and no toxic plasma concentrations were observed. Mean completion plasma concentration was 2.0 (SD 1.0) JAg/ml. No clinical toxicity was observed in either group. Fibreoptic bronchoscopy in both groups using topical lignocaine anaesthesia without premedication or intravenous supplementation was well tolerated.
Lignocaine is commonly used for topical anaesthesia of the upper respiratory tract during fibreoptic bronchoscopy. The amount of lignocaine is usually titrated to patient response during bronchoscope insertion and bronchial examination. This method often leads to the administration of large doses of lignocaine over a short period of time. Recent studies have emphasised the variable systemic absorption of lignocaine from the respiratory tract and that high, potentially toxic plasma concentrations occur. 1, 2 The problems highlighted by these studies prompted an examination of the effectiveness and safety of the standard method of titrated lignocaine topical anaesthesia for fibreoptic bronchoscopy used at our institution for many years. Patient comfort, dose of administered lignocaine and the resultant plasma concentrations were measured at four stages during bronchoscopy. Analysis of the results of the first eleven patients confirmed previous work showing high total doses of lignocaine, with variable absorption and occasional plasma concentrations in the toxic range. Patient comfort, however, was generally very good. Because of the high total doses of lignocaine used with our standard titration method, it was decided to evaluate a fixed lower dose protocol with the aim of reducing the risk of toxic AllaeSlhesllI unrllllf(,lIsi!'e Care, 1'0/. 13, So, -I, SOI'ember, 1985 plasma lignocaine concentrations. Patient comfort was again assessed to determine the efficacy of the topical anaesthesia.
METHOD
The preliminary study (Group A) involved eleven elective, fasted, adult outpatients undergoing diagnostic fibreoptic bronchoscopy. The first patient booked on each elective outpatient bronchoscopy list was prospectively studied. The bronchoscopy and the topical anaesthesia were performed by a single operator and patients scheduled for prolonged procedures such as trans-bronchial lung biopsies or alveolar lavage were excluded. Patients received no premedication or intravenous sedation during the procedure.
Topical lignocaine was titrated by the operator to patient response (e.g. coughing or straining) to facilitate passage of and examination with the bronchoscope. The actual administered dose and time were recorded by an independent observer at the following stages:
1. mask nebulisation of 2.0 ml of 4070 lignocaine for ten minutes before the procedure. Any residual lignocaine solution remaining after ten minutes was measured to derive the nebulised dose;
2. naso-oropharyngeal anaesthesia using 3-5 ml of 2% lignocaine jelly applied to the nasal passage and 8-12 met red 10% lignocaine aerosol sprays (10 mg per spray) to the oropharynx; and 3. per-bronchoscopic laryngeal and bronchial application of 2% lignocaine given in 2-3 ml increments by injection under direct vision (15-20 ml).
Venous blood samples were taken after each stage and 10 minutes after completion of the procedure for plasma lignocaine analysis. The plasma was separated and stored at -20 QC until analysis. Lignocaine was assayed using a standard clinical enzyme mediated immunoassay technique (EMIT, Syva, California, USA) by the Department of Clinical Pharmacology at the Royal Melbourne Hospital.] The assay method was accurate to a lower range of 1.0 Ilg/ml and dilutions were performed for concentrations greater than 12 Ilg/ml. The normal therapeutic plasma concentration range for clinical control of ventricular arrhythmias is 2-5 Ilg/ml.
After completion of the procedure the independent observer assessed patient comfort using a graded comfort scale with the following discomfort descriptions: 0-: no discomfort 1 -: minimal discomfort 2 -: uncomfortable 3 -: very uncomfortable 4 -: extremely uncomfortable.
The patient was shown this scale by the observer and simply asked to select a score for each stage of the procedure. The operator also gave an overall evaluation of the procedure using the same scale.
Group B contained twenty-one patients who were prospectively studied after the initial results from Group A were reviewed. It was decided to restrict the dose of topical lignocaine to a fixed 370 mg total dose protocol as follows:
(a) 1.5 ml of 4% lignocaine given via a mask nebuliser immediately before the procedure.
(b) 3 ml of 2% lignocaine jelly nasally and 5 metered sprays of 10% lignocaine aerosol to the oropharynx.
(c) 20 ml of 1 % lignocaine applied via the bronchoscope to the larynx and bronchial tree in 2 ml increments with 10 ml being given above and 10 ml below the larynx. The concentration of lignocaine, instead of the delivered volume was reduced from 2% to 1 % because of th~ practical difficulty of injecting very small volumes through the bronchoscope at multiple target sites and mucosal surfaces.
The same methods of patient selection and comfort assessment were used for group B as group A; plasma lignocaine samples were taken ten minutes after the completion of the procedure to coincide with the peak concentrations observed in Group A.
The results were analysed using the unpaired Students t-test and the Mann-Whitney statistic for comparison between groups. Analysis within groups was performed by linear regression analysis using the least squares method.
RESUL TS
Comfort assessments showed that fibreoptic bronchoscopy performed using local anaesthesia without premedication or intravenous sedation is generally well tolerated. All stages in both treatment groups produced median comfort scores of two or less with the (Table 1 ). There was no statistical difference between the comfort scores of the two groups. In Group A there was no correlation between comfort scores and either the lignocaine dose administered or the resultant plasma lignocaine concentrations. In Group B there was no correlation between patient comfort scores and completion plasma lignocaine concentrations. Lignocaine absorption in Group A was variable. The time course of lignocaine dose administration and plasma concentrations is shown in Table 2 . No patient had a detectable plasma concentration after the mask nebulisation and only two of the eleven patients had detectable concentrations after nasopharyngeal application. There was no correlation between the resultant plasma lignocaine concentrations and either the individual or total doses of lignocaine administered. One patient, a 45-year-old 62 kg man being investigated for haemoptysis, had a toxic concentration of 7.2 J-Ig/ml following a GROUP A GROUP B median range median range
220 mg bronchial dose of lignocaine and a cumulative total dose of 480 mg. His completion plasma concentration was 6.3 J-Ig/ml. In Group B, using the fixed dose of 370 mg, all patients had completion plasma lignocaine concentrations less than 5J-1g/ml while seven patients had concentrations less than 2 J-Ig/ml. The difference between the mean completion plasma lignocaine concentrations in Group A and B was not significant.
In two patients the lignocaine concentration was measured in the washings and secretions that were suctioned back through the bronchoscope during the procedure. The concentration in these fluids was greater than 50 J-Ig/ml. DISCUSSION Patient comfort and patient safety are two concurrent aims during most clinical procedures. It is clearly important to recognise when one of these aims may seriously interfere with the other.
Plasma lignocaine concentrations following upper and lower respiratory tract application have been measured before. I ,2,4,j Concentrations in the toxic range have been noted following normal clinical doses, but have not been associated with clinical complications. However, during fibreoptic bronchoscopy periods of hypoxaemia and cardiac arrhythmias are not uncommon. 6 The severity of any clinical consequences of hypoxaemia would be potentiated by toxic plasma concentrations of lignocaine. Two deaths have been reported after application of topical anaesthesia before bronchoscopic examination. J A recent editorial assessed fibreoptic bronchoscopy as an outpatient procedure. 8 Morbidity and mortality risk factors were reviewed and guidelines were recommended. These included proper patient selection with respect to age and cardiopulmonary reserve, the avoidance of sedatives or narcotics before or during the procedure, a limited dose of lignocaine of about 300 mg and adequate assistance and monitoring facilities in the procedure room.
Patients in this and other studies l. 4 have received up to twice this recommended dose and no adverse clinical consequences have been noticed. Not all patients receiving these high doses will develop high plasma concentrations. During awake fibreoptic bronchoscopy many factors including coughing, swallowing with delayed enteral absorption, differences in application technique and lignocaine formulation, and differences in absorption along the respiratory tract cause variable plasma concentrations. The high lignocaine concentration found in the aspirated secretions and lavage fluid suggests that a significant proportion of the administered dose is not available for systemic absorption, particularly in unsedated patients with intact cough reflexes.
A recent pharmacokinetic study examining lignocaine and bupivacaine absorption during awake fibreoptic bronchoscopy found peak plasma lignocaine concentrations occurred at a mean time of 35 minutes from the start of topical application, There was no statistical difference found between upper and lower respiratory tract absorption times and the mean plasma elimination half-life for lignocaine was found to be 2.3 hours, knowledge of which helps establish guidelines for patient The same study also noted that adequate operating conditions were achieved using bupivacaine at a one-eighth equivalent dose of lignocaine. Rather than a low dose of bupivacaine, this may reflect an unnecessarily high dose of lignocaine which was the finding in our Group B patients, where a lower total dose of lignocaine produced the same operating conditions and patient comfort as the higher titrated dose. Even this lower 370 mg dose may be unnecessarily high. Certainly the general feeling that 'the more local the more comfort' is not clearly supported,
If patient comfort is not a direct result of lignocaine dose or resultant plasma concentration, what other factors are important in awake unpremedicated patients? These factors need further study; however, careful explanation, reassurance and patient understanding are all extremely important, as is a sympathetic nurse holding a hand during the procedure.
All patients in this study had relatively short total procedure times. Prolonged procedures, such as trans-bronchial lung biopsy or alveolar lavage, requiring repeat lower tract topical anaesthesia may have greater toxicity potential, particularly as these procedures are more likely to be associated with an increased risk of hypoxaemia. Clearly it is important to understand the price paid to achieve adequate patient comfort in this and in all procedures.
